News | January 07, 2013

Biosensors Announces First Patient Enrolled in LEADERS FREE

January 7, 2013 — Biosensors International has announced enrollment of the first patient in LEADERS FREE, a clinical study involving BioFreedom, a polymer-free drug-coated stent (DCS) from Biosensors.

LEADERS FREE is the first prospective, randomized, double-blind trial exclusively involving patients at high risk of bleeding. The study has been designed to confirm that BioFreedom is as safe as a bare metal stent (BMS) in this patient group, and can deliver the anti-restenotic benefit of a drug-eluting stent (DES), with only a one-month course of dual antiplatelet therapy (DAPT).

BioFreedom represents the latest development in Biosensors’ stent technology, featuring a micro-structured abluminal surface, which permits the controlled release of Biolimus A9 (BA9) without the use of a polymer. BA9 is a highly lipophilic anti-restenotic drug developed by Biosensors specifically for use with stents.

The first patient has been enrolled by the study’s principal investigator Dr. Philip Urban at the Hôpital de la Tour, Geneva.

“The results of this study will be particularly important as we hope that they will show, for the first time, that a drug-coated stent can be more effective than a bare metal stent in a subgroup of patients not previously studied, yet just as safe,” Urban commented. “This study could therefore potentially change clinical practice by permitting the use of a drug-coated stent in conjunction with one month’s DAPT duration”.

LEADERS FREE is in the process of enrolling approximately 2,500 patients identified as having a high risk of bleeding from 60 sites across Europe, Asia and South America, with follow-up for two years. Patients in both arms of the study are being prescribed only one month of DAPT.

The co-primary endpoints of the study are: 1) Non-inferiority of BioFreedom compared with BMS as measured by specific safety factors (cardiac death, myocardial infarction and definite/probable stent thrombosis) after one year and; 2) Superiority over BMS in terms of clinically-driven TLR at 12 months.

Investigators anticipate completing the enrollment process by early 2014. Primary endpoint data is likely to be presented during 2015.

“We anticipate that the results from LEADERS FREE will bring real benefits to patients at high risk of bleeding, who cannot currently be given a drug-eluting stent due to the need for a prolonged course of DAPT,” said Jeffrey B. Jump, president of Biosensors’ Cardiovascular Business Unit. “With BioFreedom, they will now be able to benefit from a stent with an anti-restenotic drug, yet still only take a month-long course of DAPT”.

Three-year results from the BioFreedom FIM study were presented at TCT on Oct. 23, 2012. They showed similar rates of MACE (a composite of all death, MI, emergent cardiac artery bypass graft [CABG] and target lesion revascularization [TLR]) between BioFreedom and Boston Scientific’s Taxus Liberté DES (11.9 percent vs. 10.0 percent), with no evidence of stent thrombosis in either group.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init